Bausch Taps Barr to Head Local Unit

Reed, Vita
May 2012
Orange County Business Journal;5/21/2012, Vol. 35 Issue 21, p1
The article offers information on Bausch & Lomb Inc. John Barr's appointment as the company's president in surgical business, replacing Robert Grant, comes in advance of its pending acquisition with Ista Pharmaceuticals Inc. The U.S. Securities and Exchange Commision (SEC) mentions that Ista shareholders are scheduled to vote on June 5, 2012. Ista contacted potential acquirers such as Bausch and Valeant Pharmaceuticals International Inc. for the potential deal filing.


Related Articles

  • Bausch & Lomb Tops Valeant with US$500 M Bid for ISTA. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 4, p49 

    After rejecting a hostile US$7.50 per share takeover bid from Valeant Pharmaceuticals International earlier in 2012, ISTA Pharmaceuticals has accepted a US$9.10 per share offer from Bausch & Lomb (B&L), which equates to a total deal value of approximately US$500 M. The transaction, which has...

  • R&D Pipeline Prompted Bausch & Lomb's Ista Buy. Reed, Vita // Orange County Business Journal;4/9/2012, Vol. 35 Issue 15, p54 

    The article offers information related to business enterprises in California. It states that the 500 million dollars pending acquisition of Ista Pharmaceuticals Inc. by Bausch & Lomb Inc. was motivated by products in its Irvine-based pipeline. It says that Robert Grant was appointed as chairman...

  • IN THE NEWS.  // Review of Optometry;Jun2014, Vol. 151 Issue 6, p4 

    The article offers optometry news briefs as of June 15, 2014 on topics including acquisition of supplier of eye health products Bausch & Lomb by Valeant Pharmaceuticals, study on link between vasodilators and Age-related Macular Degeneration development and risks of visual correction.

  • B&L buyout is completed.  // Optometry Today;9/6/2013, Vol. 53 Issue 17, p7 

    The article reports that the acquisition of the eye health company Bausch & Lomb Inc. (B&L) by Valeant Pharmaceuticals was already completed in August 2013.

  • Valeant to Buy B+L.  // Review of Cornea & Contact Lenses;Jun2013, Vol. 150 Issue 5, p5 

    The article reports on Canada's Valeant Pharmaceuticals' acquisition of Bausch + Lomb, the first company to introduce soft contact lens, for 8.7 billion dollars.

  • Valeant Shifts OC Eye Surgery Operations to Spectrum. REED, VITA // Orange County Business Journal;1/13/2014, Vol. 37 Issue 2, p7 

    The article focuses on the relocation of Canadian-based drug manufacturer Valeant Pharmaceuticals International's eye surgical business from Aliso Viejo, California to Irvine Spectrum, and mentions the consolidation of the company to eye health company Bausch + Lomb Inc.

  • Valeant acquires B&L for $8.7bn.  // Optometry Today;6/14/2013, Vol. 53 Issue 12, p5 

    The article reports on an announcement by Valeant Pharmaceuticals International about its decision to purchase Bausch & Lomb (B&L) for 8.7 billion dollars as of June 2013.

  • Valeant to buy Bausch + Lomb for $8.7 billion.  // Chain Drug Review;6/17/2013, Vol. 35 Issue 10, p8 

    The article informs that Valeant Pharmaceuticals International Inc. will acquire the health care firm Bausch + Lomb Inc. by paying 8.7 billion dollars and mentions that the money will be used to pay 4.5 billion dollars to an investor group and rest will be used to repay Bausch's debt.

  • Ista Doesn't Budge; More Suitors Seen. Reed, Vita // Orange County Business Journal;2/6/2012, Vol. 35 Issue 6, p1 

    The article reports on the rejection of Ista Pharmaceuticals Inc. to the offer of Valeant Pharmaceuticals International Inc. due to various potential suitors for its acquisition and demand for up to 530 million dollars which is higher than Valeant's.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics